The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

Three more successful launches cited by Trinity were for RSV vaccines, each of which significantly exceeded expectations. Those shots were GSK’s Arexvy, Pfizer’s Abrysvo and Sanofi and ...

The Alberta government is permanently cutting off the flow of publicly funded vaccines to community medical clinics, save a select few, sparking yet another wave of concern from health-care providers.

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo in the market. It will need to get endorsement from the Centers for Disease Control and Prevention (CDC ...

The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...